New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 29, 2017 – Novo Nordisk announced the FDA approval of Fiasp (insulin aspart) to improve glycemic control in adults with diabetes mellitus.
Download PDF
Return to publications
